pegfilgrastim

Pegfilgrastim is a PEGylated, long-acting form of recombinant human granulocyte colony-stimulating factor (G-CSF) analog filgrastim. It is used to reduce the risk of infection, as demonstrated by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Pegfilgrastim works by binding to the granulocyte colony-stimulating factor receptor on hematopoietic cells in the bone marrow, stimulating proliferation and differentiation into neutrophils—white blood cells essential for fighting infection. The addition of polyethylene glycol (PEG) extends its half-life compared to filgrastim, allowing for less frequent dosing. Pegfilgrastim was developed by Amgen and first approved in 2002[3][4][8]. It is also indicated to increase survival after acute exposure to myelosuppressive doses of radiation[3].

Brand names

NeulastaFulphilaFylnetraNyvepriaStimufendUdenycaZiextenzo

Other names

pegylated recombinant human granulocyte colony-stimulating factorglycoPEGylated G-CSF